20 recruiting, 10 active not recruiting, 5 completed, 2 not yet recruiting. 43 Phase 2, 10 Phase 1, 1 Phase 3.
Follow Pluvicto: new trials by email Literature Review of Pluvicto trials Research Report on Pluvicto
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer Abiraterone Acetate, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 432 | 2027-01-06 | 2026-10-01 |
| Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial Lutetium Lu 177 Vipivotide Tetraxetan, Cell-free Circulating Tumor DNA Assay, Computed Tomography - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | University of Washington | 64 | 2026-11-15 | 2026-10-19 |
| Pluvicto for the Treatment of African American Men With Metastatic Castration-Resistant Prostate Cancer Biopsy Procedure, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Not yet recruiting | Emory University | 88 | 2026-11-02 | 2026-10-06 |
| PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT EBRT + 6 mo ADT + 177Lu-PSMA-617, EBRT + 24 mo ADT - High-Risk Localized Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 60 | 2026-08-17 | 2026-09-22 |
| Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial Abiraterone Acetate, Biospecimen Collection, Leuprolide Acetate - Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Mayo Clinic | 202 | 2026-08-04 | 2026-09-18 |
| 68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC) Lu-PSMA-617 - Liver Cancer, Hepatocellular Carcinoma | Phase 2 | Recruiting | Melissa Lumish | 10 | 2026-06-01 | 2026-05-08 |
| Radiopharmaceutical Treatment of Advanced Kidney Cancer 177Lu-PSMA-617 - Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 48 | 2026-04-07 | 2026-06-04 |
| Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma Actinium Ac 225 Vipivotide Tetraxetan, Biospecimen Collection, Gallium Ga 68 Gozetotide - Oligometastatic Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 107 | 2025-12-12 | 2026-09-17 |
| A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC AMO959, AAA617, Enzalutamide - PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 123 | 2025-12-05 | 2026-10-15 |
| An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC AAA617, ARPI: Abiraterone, ARPI: Enzalutamide - Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 7 | 2025-09-11 | 2026-10-21 |
| 177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia 177Lu-PSMA-617 - Metastatic Castration Resistant Prostate Cancer, Cytopenia | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2025-08-03 | 2026-05-08 | |
| 177LuPSMA in Renal Cell Carcinoma 177Lu-PSMA-617 - Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 24 | 2025-07-31 | 2026-02-24 |
| Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer Cabazitaxel and carboplatin, Lu-PSMA-617 - Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Case Comprehensive Cancer Center | 44 | 2025-07-14 | 2026-10-02 |
| A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) JSB462, AAA617 - Prostatic Cancer, Castration-Resistant | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 138 | 2025-07-03 | 2026-10-09 |
| Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617 Administering Lutetium-177-PSMA-617 (PLUVICTO) - Metastatic Castration-Resistant Prostate Cancer, Prostate Cancer Patients With Bone Metastasis | Phase 2 | Recruiting | Ebrahim S Delpassand | 30 | 2025-05-23 | 2025-05-15 |
| STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer Lu-PSMA-617, 5-fraction Stereotactic Body Radiation Therapy (SBRT) - Malignant Neoplasm of Prostate, Locally Advanced Prostate Cancer | Phase 1 / Phase 2 | Recruiting | Angela Y. Jia, MD PhD | 45 | 2025-05-13 | 2026-05-26 |
| Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease Biospecimen Collection, Bone Scan, Computed Tomography - Metastatic Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | University of Washington | 51 | 2025-04-29 | 2026-07-07 |
| Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer [177Lu]Lu-PSMA-617 (Pluvicto, Novartis) - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Hospices Civils de Lyon | 58 | 2025-04-11 | 2026-01-06 |
| Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial Genetic testing, Valemetostat Tosylate, Magnetic Resonance Imaging - Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Alliance for Clinical Trials in Oncology | 474 | 2025-02-06 | 2026-10-02 |
| 177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer Lutetium (177Lu) vipivotide tetraxetan - Prostate Cancer | Phase 2 | Recruiting | Maria Sklodowska-Curie National Research Institute of Oncology | 200 | 2025-01-09 | 2026-10-16 |
Showing 20 of 43. Sign in to see all of them.
Prostatic Neoplasms (29) · Kidney Neoplasms (2) · Anemia (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Clear-cell metastatic renal cell carcinoma (1) · Cytopenia (1) · Genital Neoplasms, Male (1) · Liver Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Neoplasms by Site (1) · Prostatic Diseases (1) · Prostatic Neoplasms, Castration-Resistant (1) · Renal Insufficiency (1)
Novartis Pharmaceuticals (6) · Jonsson Comprehensive Cancer Center (3) · Peter MacCallum Cancer Centre, Australia (3) · Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2) · Mayo Clinic (2) · Radboud University Medical Center (2) · University of Washington (2) · Weill Medical College of Cornell University (2) · Alliance for Clinical Trials in Oncology (1) · Angela Y. Jia, MD PhD (1) · Baptist Health South Florida (1) · Canadian Cancer Trials Group (1) · Case Comprehensive Cancer Center (1) · Dana-Farber Cancer Institute (1) · ECOG-ACRIN Cancer Research Group (1)
United States (29) · Australia (7) · France (6) · Germany (4) · Italy (4) · Spain (4) · Canada (3) · Netherlands (3) · Czechia (2) · Japan (2) · Poland (2) · Singapore (2) · South Korea (2) · Austria (1) · Brazil (1)
James Nagarajah, Prof. (2) · Michael Schweizer (2) · Scott Tagawa, MD (2) · Amar Kishan (1) · Ana Kiess (1) · Angela Castellanos Rodriguez, MD, MSc (1) · Angela Y Jia, MD, PhD (1) · Arun Azad, MBBS PhD FRACP (1) · Bagi Jana, MD (1) · Daniel E Spratt, MD (1) · David Wise, MD (1) · Declan Murphy (1) · Ebrahim S. Delpassand, M.D. Chairman & Medical Director, MD., Nuclear Medicine (1)
PMID 33465252, PMID 31595044, PMID 32928177, PMID 33581798, PMID 33883176, PMID 34246328, PMID 34373282, PMID 34736509, PMID 36261050, PMID 36350899, PMID 36692682, PMID 37891072, PMID 38043558, PMID 39293461, PMID 39978808, PMID 40425844, PMID 40638023, PMID 40876952, PMID 41073165, PMID 41545068, PMID 41679923, PMID 41785440, PMID 41926960
2023 (1), 2025 (1), I01CX002775 (1), P30CA138292 (1), R37CA286450 (1), U10CA180820 (1)